Hepatitis Monthly

Published by: Kowsar

The Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised

Abbas Tavakolian Arjmand 1 , * and Nasrin Razavianzadeh 1
Authors Information
1 Internal Medicine Department, Shahrood Medical School, Islamic Azad University, Semnan, IR Iran
Article information
  • Hepatitis Monthly: September 01, 2016, 16 (9); e36485
  • Published Online: August 16, 2016
  • Article Type: Letter
  • Received: January 20, 2016
  • Revised: August 6, 2016
  • Accepted: August 6, 2016
  • DOI: 10.5812/hepatmon.36485

To Cite: Tavakolian Arjmand A, Razavianzadeh N. The Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised, Hepat Mon. 2016 ; 16(9):e36485. doi: 10.5812/hepatmon.36485.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7): 434-8[PubMed]
  • 2. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999; 29(3): 664-9[DOI][PubMed]
  • 3. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005; 22 Suppl 2: 24-7[DOI][PubMed]
  • 4. Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991; 44(6): 465-74[PubMed]
  • 5. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med. 2005; 22(8): 973-9[DOI][PubMed]
  • 6. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002; 25(5): 815-21[PubMed]
  • 7. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999; 22(5): 756-61[PubMed]
  • 8. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007; 30(3): 734-43[DOI][PubMed]
  • 9. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85(10): 1349-55[PubMed]
  • 10. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004; 2(3): 262-5[PubMed]
  • 11. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009; 16(2): 141-9[DOI][PubMed]
  • 12. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000; 32(4 Pt 1): 689-92[DOI][PubMed]
  • 13. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007; 30(11): 2940-4[DOI][PubMed]
  • 14. Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, et al. Does this patient with liver disease have cirrhosis? JAMA. 2012; 307(8): 832-42[DOI][PubMed]
  • 15. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997; 92(8): 1302-4[PubMed]
  • 16. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001; 96(8): 2462-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments